--- title: "Short Interest in Kenvue Inc. (NYSE:KVUE) Grows By 47.9%" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/213119551.md" description: "Kenvue Inc. (NYSE:KVUE) experienced a significant increase in short interest by 47.9% in August, reaching a total of 44,750,000 shares. This signifies that approximately 2.3% of the company's shares are currently shorted, with a days-to-cover ratio of 2.4 days, based on an average trading volume of 18,780,000 shares. The company reported earnings of $0.32 per share, exceeding expectations. Kenvue also recently adjusted its dividend, now yielding 3.74%. Various analysts have mixed ratings on the stock, with a consensus hold rating and an average price target of $20.64." datetime: "2024-09-01T00:40:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/213119551.md) - [en](https://longbridge.com/en/news/213119551.md) - [zh-HK](https://longbridge.com/zh-HK/news/213119551.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/213119551.md) | [English](https://longbridge.com/en/news/213119551.md) # Short Interest in Kenvue Inc. (NYSE:KVUE) Grows By 47.9% Kenvue Inc. (NYSE:KVUE - Get Free Report) was the target of a large increase in short interest in August. As of August 15th, there was short interest totalling 44,750,000 shares, an increase of 47.9% from the July 31st total of 30,250,000 shares. Based on an average daily volume of 18,780,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 2.3% of the company's stock are short sold. ## Kenvue Stock Performance - Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon NYSE KVUE traded up $0.20 on Friday, hitting $21.95. 14,008,532 shares of the stock were exchanged, compared to its average volume of 18,622,010. The company has a market capitalization of $42.03 billion, a PE ratio of 28.14, a P/E/G ratio of 2.07 and a beta of 1.38. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68. The business's fifty day moving average is $19.54 and its 200 day moving average is $19.56. Kenvue has a 52 week low of $17.67 and a 52 week high of $23.33. Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The company had revenue of $4 billion for the quarter, compared to analysts' expectations of $3.93 billion. During the same period in the prior year, the firm earned $0.32 EPS. Kenvue's quarterly revenue was down .3% compared to the same quarter last year. Research analysts anticipate that Kenvue will post 1.13 EPS for the current fiscal year. ## Kenvue Increases Dividend - This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.74%. This is a boost from Kenvue's previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Wednesday, August 14th. Kenvue's dividend payout ratio (DPR) is presently 105.13%. ## Analysts Set New Price Targets KVUE has been the subject of a number of research reports. Citigroup lowered their target price on Kenvue from $21.00 to $20.00 and set a "neutral" rating for the company in a report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft lifted their target price on Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. HSBC upped their price target on Kenvue from $20.00 to $21.00 and gave the stock a "hold" rating in a research report on Wednesday, May 8th. Royal Bank of Canada reiterated an "outperform" rating and issued a $24.00 price objective on shares of Kenvue in a report on Wednesday, August 7th. Finally, UBS Group boosted their price objective on shares of Kenvue from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $22.64. - Johnson & Johnson is as Cheap as it’s Going to Get **Read Our Latest Report on Kenvue** ## Institutional Inflows and Outflows A number of institutional investors have recently made changes to their positions in the business. Manchester Capital Management LLC lifted its position in Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company's stock worth $25,000 after acquiring an additional 530 shares during the last quarter. Pacific Capital Wealth Advisors Inc. bought a new position in Kenvue during the 4th quarter worth $28,000. Mather Group LLC. bought a new stake in shares of Kenvue in the first quarter valued at approximately $28,000. Riverview Trust Co bought a new stake in shares of Kenvue during the 1st quarter valued at $33,000. Finally, MV Capital Management Inc. grew its holdings in shares of Kenvue by 71.2% during the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company's stock worth $33,000 after purchasing an additional 642 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds. ## About Kenvue (Get Free Report) Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. ## Featured Stories - Five stocks we like better than Kenvue - The Basics of Support and Resistance - Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win - Where to Find Earnings Call Transcripts - Why Dell Can Continue Winning in AI and Beyond - Industrial Products Stocks Investing - Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com._ → Our #1 Gold Trade for 2024 (From Behind the Markets) (Ad) ## Should you invest $1,000 in Kenvue right now? Before you consider Kenvue, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list. While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### 相關股票 - [Kenvue (KVUE.US)](https://longbridge.com/zh-HK/quote/KVUE.US.md) ## 相關資訊與研究 - [FACTBOX-Big-ticket consumer deals over past few decades](https://longbridge.com/zh-HK/news/281008143.md) - [ENvue Medical Expands Presence within a Major Michigan Health System and Grows U.S. Hospital Footprint to 39 | FEED Stock News](https://longbridge.com/zh-HK/news/280313563.md) - [A Look Into Kenvue Inc's Price Over Earnings](https://longbridge.com/zh-HK/news/271829340.md) - [Lecap Asset Management Ltd. Acquires Shares of 60,290 Kenvue Inc. $KVUE](https://longbridge.com/zh-HK/news/272069537.md) - [What's Driving the Market Sentiment Around Kenvue Inc?](https://longbridge.com/zh-HK/news/271685209.md)